Loading
NASDAQHealthcareMedical - Pharmaceuticals
Latest quote
$0.851
+$0.001 · +0.12%
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Previous close
$0.851
+$0.001 · +0.12%
After-hours
$0.8593
+$0.0083 · +0.98%
Oct 7, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Day range
Current $0.851
52-week range
Current $0.851
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
41
Fair Value
Sentiment
44
Mixed
Risk
97
Extreme Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Day range
Current $0.851
52-week range
Current $0.851
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | 6.42M USD | 4.93M USD | 4.24M USD | 6.86M USD |
| Selling, general, and administrative | 17.1M USD | 15.65M USD | 7.88M USD | 2.86M USD |
| Operating expenses | 23.52M USD | 20.57M USD | 12.12M USD | 9.71M USD |
| Interest income | 36.37K USD | — | — | — |
| Interest expense | 218.03K USD | — | — | — |
| Depreciation and amortization | — | — | — | 9.71M USD |
| Operating income | −23.52M USD | −20.57M USD | −12.12M USD | −9.71M USD |
| Net income | −24.76M USD | −21.15M USD | −12.7M USD | −10.87M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
